Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 5/20 | 0.52 |
| ▸ | JAK2 | O60674 | 4/20 | 0.52 |
| ▸ | JAK1 | P23458 | 4/20 | 0.52 |
| ▸ | JAK3 | P52333 | 4/20 | 0.52 |
| ▸ | GNRHR | P30968 | 1/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
| ▸ | TBK1 | Q9UHD2 | 6/20 | 0.33 |
| ▸ | EGLN2 | Q96KS0 | 3/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18409158 | 0.91 | TYK2 (0.58) | TYK2JAK2JAK1JAK3GNRHR | |
| SCHEMBL18409528 | 0.88 | TYK2 (0.65) | TYK2JAK2JAK1JAK3GNRHR | |
| SCHEMBL18409450 | 0.86 | TYK2 (0.47) | TYK2JAK2JAK1JAK3GNRHR | |
| SCHEMBL18409176 | 0.83 | TYK2 (0.48) | TYK2JAK2JAK1JAK3GNRHR | |
| SCHEMBL18409159 | 0.83 | TYK2 (0.48) | TYK2JAK2JAK1JAK3ABL1 | |
| SCHEMBL18398336 | 0.81 | JAK2 (0.38) | TYK2JAK2JAK1JAK3 | |
| SCHEMBL18398297 | 0.81 | GPR6 (0.37) | TYK2JAK2JAK1JAK3 | |
| SCHEMBL18409163 | 0.81 | TYK2 (0.75) | TYK2JAK2JAK1JAK3GNRHR | |
| SCHEMBL18409345 | 0.81 | JAK2 (0.50) | TYK2JAK2JAK1JAK3ABL1 | |
| SCHEMBL18409204 | 0.80 | JAK2 (0.45) | TYK2JAK2JAK1JAK3EGLN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017012647-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2017-01-26 | — | — | WO | disclosed |